Skip to main content
. 2022 Feb 2;7:13. doi: 10.1038/s41536-022-00208-9

Fig. 1. Local and systemic administration of MBV significantly reduces both acute and chronic pristane-induced arthritis disease severity.

Fig. 1

a Experimental design and treatment regimen. b Representative images of forepaws and hind paws for each group at day 0 and day 100. Evident edema, erythema, and distortion of the forepaws and hind paws were evident in the Pristane + PBS group but not in the remaining treatment groups. c I.p. methotrexate significantly reduces disease scoring between days 10–28 and days 70–100 compared to Pristane + PBS (p < .05) d P.a. MBV significantly reduces disease scoring between days 10–35 and days 70–100 compared to Pristane + PBS (p < 0.05). e I.v. MBV significantly reduce disease scoring between days 14–35 and days 63–100 compared to Pristane + PBS (p < 0.05). All values represented in panels c–e are mean ± s.e.m., n = 12 for days 7–28, and n = 8 days 28–100.